Clinical Trials in Progress: Bladder Cancer

Sunday, May 17, 2026 9:00 AM to 11:00 AM · 2 hr. (America/New_York)

Hall B, The Square, Learning Lab

Learning Lab

New Technologies/Instruments/DevicesOncology: Bladder

Information

Of Interest To

Researchers

Sunday, May 17

Sunday, May 17, 2026 9:00 AM to 9:08 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 9:08 AM to 9:16 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 9:16 AM to 9:24 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 9:24 AM to 9:32 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 9:32 AM to 9:40 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 9:40 AM to 9:48 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 9:48 AM to 9:56 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 9:56 AM to 10:04 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 10:04 AM to 10:12 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 10:12 AM to 10:20 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 10:20 AM to 10:28 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 10:28 AM to 10:36 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 10:36 AM to 10:44 AM

Hall B, The Square, Learning Lab

Sunday, May 17, 2026 10:44 AM to 10:52 AM

Hall B, The Square, Learning Lab

Registered attendees

Atanu Kumar Pal

Vattikuti Fellow of Robotic Urologic SurgeryAster Medcity Kochi, Kerala, India

Yakov Klugman

Medical StudentRoswell Park Comprehensive Cancer Center

Clinical Trials in Progress: Bladder Cancer

Information

Sunday, May 17

Safety and Efficacy of Bel-sar (AU-011), a Virus-Like Drug Conjugate, in Participants with Non-Muscle Invasive Bladder Cancer (NMIBC)

SWOG S2611 (ARCIS) A Randomized Comparison of Intravesical Therapies: A phase III study of cretostimogene grenadenorepvec/gemcitabine (CRETO-GEM) versus gemcitabine/docetaxel (GEM-DOCE) for the treatment of BCG-unresponsive and BCG-exposed NMIBC

ENLIGHTED Phase 3 Trial of Non-Thermal, Drug-Activated Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP) for Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC)

A Phase II Study of Intravesical HM-001 in Patients with Non–Muscle-Invasive Bladder Cancer Following Safe Completion of a Phase I Trial

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with FGFR3-Altered Low-Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics

MoonRISe-3: a phase 3 study of erda-iDRS, an erdafitinib intravesical drug-releasing system, vs intravesical chemotherapy in patients with bacillus Calmette-Guérin–treated high-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations

Trial in Progress: REL-NDV01-301 (BOOST) - A Phase 3, Randomized Study of Adjuvant Intravesical Sustained-Release Gemcitabine-Docetaxel (NDV-01) Versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer

A phase 1/2 study of intravesical MK-3120 in participants with Bacillus Calmette-Guérin (BCG)-Naive or BCG-exposed high-risk non–muscle invasive bladder cancer

THE GAIN TRIAL: Gemcitabine Alternating with INtravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high grade NMIBC (ALLIANCE A032303/ NCT07000084)

HIVEC®-HEAT (Hyperthermic intravesical mitomycin [Mitomycin medac]) for patients with BCG-unresponsive nonmuscle-invasive bladder cancer trial

Gastrointestinal Recovery After Radical Cystectomy: Coffee Or Entereg For Enhanced Recovery (GI-COFEE) Trial

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy: The Randomized TIDE (Timed Intravenous Fluid Delivery for ERAS) Trial

The phase 1/2 ResQ133A-NMIBC trial: A study of intravesical recombinant Mycobacterium Bacillus Calmette‑Guérin (rBCG) in BCG‑naïve participants with non‑muscle‑invasive bladder cancer (NMIBC)

Registered attendees

Log in

Clinical Trials in Progress: Bladder Cancer

Information

Sunday, May 17

Safety and Efficacy of Bel-sar (AU-011), a Virus-Like Drug Conjugate, in Participants with Non-Muscle Invasive Bladder Cancer (NMIBC)

SWOG S2611 (ARCIS) A Randomized Comparison of Intravesical Therapies: A phase III study of cretostimogene grenadenorepvec/gemcitabine (CRETO-GEM) versus gemcitabine/docetaxel (GEM-DOCE) for the treatment of BCG-unresponsive and BCG-exposed NMIBC

ENLIGHTED Phase 3 Trial of Non-Thermal, Drug-Activated Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP) for Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC)

A Phase II Study of Intravesical HM-001 in Patients with Non–Muscle-Invasive Bladder Cancer Following Safe Completion of a Phase I Trial

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with FGFR3-Altered Low-Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics

MoonRISe-3: a phase 3 study of erda-iDRS, an erdafitinib intravesical drug-releasing system, vs intravesical chemotherapy in patients with bacillus Calmette-Guérin–treated high-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations

Trial in Progress: REL-NDV01-301 (BOOST) - A Phase 3, Randomized Study of Adjuvant Intravesical Sustained-Release Gemcitabine-Docetaxel (NDV-01) Versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer

A phase 1/2 study of intravesical MK-3120 in participants with Bacillus Calmette-Guérin (BCG)-Naive or BCG-exposed high-risk non–muscle invasive bladder cancer

THE GAIN TRIAL: Gemcitabine Alternating with INtravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high grade NMIBC (ALLIANCE A032303/ NCT07000084)

HIVEC®-HEAT (Hyperthermic intravesical mitomycin [Mitomycin medac]) for patients with BCG-unresponsive nonmuscle-invasive bladder cancer trial

Gastrointestinal Recovery After Radical Cystectomy: Coffee Or Entereg For Enhanced Recovery (GI-COFEE) Trial

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy: The Randomized TIDE (Timed Intravenous Fluid Delivery for ERAS) Trial

The phase 1/2 ResQ133A-NMIBC trial: A study of intravesical recombinant Mycobacterium Bacillus Calmette‑Guérin (rBCG) in BCG‑naïve participants with non‑muscle‑invasive bladder cancer (NMIBC)

Registered attendees

Log in

The phase 1/2 ResQ133A-NMIBC trial: A study of intravesical recombinant Mycobacterium Bacillus Calmette‑Guérin (rBCG) in BCG‑naïve participants with non‑muscle‑invasive bladder cancer (NMIBC)